Zhejiang Anglikang Pharmaceutical Hits Day Low at CNY 27.01 Amid Price Pressure

Zhejiang Anglikang Pharmaceutical Co. experienced significant activity on July 17, 2026, with the stock declining by 10.0% and reaching an intraday low of CNY 27.01. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by only 3.05% on the same day. Over the past year, Zhejiang Anglikang has faced considerable challenges, with a staggering decline of 40.1%, while the market has seen a positive return of 7.03%. The company's performance metrics reveal a mixed picture; despite a return on equity of 9.35%, net sales have only grown at an annual rate of 1.80% over the last five years, and operating profit has decreased by 1.58% during the same period. The company's financial ratios indicate a high price-to-book value of 3.37 and a dividend yield of 0.82%. However, the inventory turnover ratio is notably low at 1.82 times, suggesting potential inefficiencies in inventory management. As Zhejiang Anglikang navigates these financial dynamics, its recent stock performance reflects broader trends within the pharmaceuticals and biotechnology sector.